Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers

American Journal of Pathology

Volumn 163, Issue 3, 2003, Pages 1109-1116

  Masuda, Akira ^a   Maeno, Ken ^c   Nakagawa, Taku ^c   Saito, Hiroko ^c   Takahashi, Takashi ^b  

^a CellSeed Inc   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE INHIBITOR; CISPLATIN; DOCETAXEL; NOCODAZOLE; PACLITAXEL; STAUROSPORINE; VINORELBINE DITARTRATE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL STRAIN A549; CELL STRAIN NCI H460; CHROMOSOME STRUCTURE; CONTROLLED STUDY; DNA DAMAGE; ENZYME INHIBITION; HUMAN; HUMAN CELL; LUNG CANCER; MICROTUBULE ASSEMBLY; MITOSIS INHIBITION; MITOSIS SPINDLE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0042926426     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63470-0     Document Type: Article

References (33)

1. Hartwell LH, Weinert TA: Checkpoints: controls that ensure the order of cell cycle events. Science 1989, 246:629-634
2. Elledge SJ: Cell cycle checkpoints: preventing an identity crisis. Science 1996, 274:1664-1672
3. Takahashi T, Haruki N, Nomoto S, Masuda A, Saji S, Osada H, Takahashi T: Identification of frequent impairment of the mitotic checkpoint and molecular analysis of the mitotic checkpoint genes, hsMAD2 and p55CDC, in human lung cancers. Oncogene 1999, 18:4295-4300
4. Rudner AD, Murray AW: The spindle assembly checkpoint. Curr Opin Cell Biol 1996, 8:773-780
5. Lengauer C, Kinzler KW, Vogelstein B: Genetic instabilities in human cancers. Nature 1998, 396:643-649
6. Masuda A, Takahashi T: Chromosome instability in human lung cancers: its possible underlying mechanisms and potential consequences in the pathogenesis. Oncogene 2002, 21:6884-6897
7. Taylor SS, McKeon F: Kinetochore localization of murine Bub1 is required for normal mitotic timing and checkpoint response to spindle damage. Cell 1997, 89:727-735
8. Weitzel DH, Vandre DD: Differential spindle assembly checkpoint response in human lung adenocarcinoma cells. Cell Tissue Res 2000, 300:57-65
9. Hida T, Ariyoshi Y, Kuwabara M, Sugiura T, Takahashi T, Hosoda K, Niitsu Y, Ueda R: Glutathione S-transferase pi levels in a panel of lung cancer cell lines and its relation to chemo-radiosensitivity. Jpn J Clin Oncol 1993, 23:14-19
10. Juan G, Traganos F, James WM, Ray JM, Roberge M, Sauve DM, Anderson H, Darzynkiewicz Z: Histone H3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G2 and mitosis. Cytometry 1998, 32:71-77
11. Wang LG, Liu XM, Kreis W, Budman DR: The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 1999, 44:355-361
12. Wang TH, Wang HS, Soong YK: Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 2000, 88:2619-2628
13. Hall LL, Th'ng JP, Guo XW, Teplitz RL, Bradbury EM: A brief staurosporine treatment of mitotic cells triggers premature exit from mitosis and polyploid cell formation. Cancer Res 1996, 56:3551-3559
14. Perez-Soler R, Kemp B, Wu QP, Mao L, Gomez J, Zeleniuch-Jacquotte A, Yee H, Lee JS, Jagirdar J, Ling YH: Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin Cancer Res 2000, 6:4932-4938
15. Gorcalves A, Braguer D, Kamath K, Martello L, Briand C, Horwitz S, Wilson L, Jordan MA: Resistance to taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci USA 2001, 98:11737-11742
16. Kasai T, Iwanaga Y, Iha H, Jeang KT: Prevalent loss of mitotic spindle checkpoint in adult T-cell leukemia confers resistance to microtubule inhibitors. J Biol Chem 2002, 277:5187-5193
17. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA: Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nat Med 1996, 2:72-79
18. King TC, Akerley W, Fan AC, Moore T, Mangray S, Hsiu Chen M, Safran H: p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma. Cancer 2000, 89:769-773
19. Jordan MA, Toso RJ, Thrower D, Wilson L: Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993, 90:9552-9556
20. Basu A, Haldar S: Microtubule-damaging drugs triggered bcl2 phosphorylation-requirement of phosphorylation on both serine-70 and serine-87 residues of bcl2 protein. Int J Oncol 1998, 13:659-664
21. Haldar S, Jena N, Croce CM: Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 1995, 92:4507-4511
22. Haldar S, Basu A, Croce CM: Bcl2 is the guardian of microtubule integrity. Cancer Res 1997, 57:229-233
23. Ling YH, Tornos C, Perez-Soler R: Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis. J Biol Chem 1998, 273:18984-18991
24. Huisman C, Ferreira CG, Broker LE, Rodriguez JA, Smit EF, Postmus PE, Kruyt FA, Giaccone G: Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460. Clin Cancer Res 2002, 8:596-606
25. Davis PD, Hill CH, Keech E, Lawton G, Nixon JS, Sedgwick AD, Wadsworth J, Westmacott D, Wilkinson SE: Potent selective inhibitors of protein kinase C. FEBS Lett 1989, 259:61-63
26. Herbert JM, Seban E, Maffrand JP: Characterization of specific binding sites for [3H]-staurosporine on various protein kinases. Biochem Biophys Res Commun 1990, 171:189-195
27. Paulson JR, Patzlaff JS, Vallis AJ: Evidence that the endogenous histone H1 phosphatase in HeLa mitotic chromosomes is protein phosphatase 1, not protein phosphatase 2A. J Cell Sci 1996, 109: 1437-1447
28. Moasser MM, Sepp-Lorenzino L, Kohl NE, Oliff A, Balog A, Su DS, Danishefsky SJ, Rosen N: Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothitones. Proc Natl Acad Sci USA 1998, 95:1369-1374
29. Gualberto A, Aldape K, Kozakiewicz K, Tisty TD: An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc Natl Acad Sci USA 1998, 95:5166-5171
30. Haruki N, Harano T, Masuda A, Kiyono T, Takahashi T, Tatematsu Y, Shimizu S, Mitsudomi T, Konishi H, Osada H, Fujii Y, Takahashi T: Persistent increase in chromosome instability in lung cancer: possible indirect involvement of p53 inactivation. Am J Pathol 2001, 159: 1345-1352
31. Lehman TA, Bennett WP, Metcalf RA, Welsh JA, Ecker J, Modali RV, Ullrich S, Romano JW, Appella E, Testa JR, Gerwin BI, Harris CC: p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res 1991, 51:4090-4096
32. Jia LQ, Osada M, Ishioka C, Gamo M, Ikawa S, Suzuki T, Shimodaira H, Niitani T, Kudo T, Akiyama M, Kimura N, Matsuo M, Mizusawa H, Tanaka N, Koyama H, Namba M, Kanamaru R, Kuroki T: Screening the p53 status of human cell lines using a yeast functional assay. Mol Carcinog 1997, 19:243-253
33. Scheffner M, Munger K, Byrne JC, Howley PM: The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci USA 1991, 88:5523-5527